Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > POC in humans has been acheived is that it

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon May 02, 2024 7:00pm

74 Views

Post# 36020620

RE:RE:RE:RE:RE:RE:RE:RE:POC in humans has been acheived is that it

That stuff always leaks and by looks of it it's nothing to get too excited about. They need to show very good efficcaity and I'm not sure they can afford to do it or convince someone else to do it for them. Egrifta works in Nash and they coul'nt even do that in the last 3 years. Anyway lets hope it works.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec